Abstract |
Targeted therapy and imaging are the most popular techniques for the intervention and diagnosis of cancer. A potential therapeutic target for the treatment of cancer is the epidermal growth factor receptor (EGFR), primarily for glioblastoma, lung, and breast cancer. Over-production of ligand, transcriptional up-regulation due to autocrine/paracrine signalling, or point mutations at the genomic locus may contribute to the malfunction of EGFR in malignancies. This exploit makes use of EGFR, an established biomarker for cancer diagnostics and treatment. Despite considerable development in the last several decades in making EGFR inhibitors, they are still not free from limitations like toxicity and a short serum half-life. Nanobodies and antibodies share similar binding properties, but nanobodies have the additional advantage that they can bind to antigenic epitopes deep inside the target that conventional antibodies are unable to access. For targeted therapy, anti-EGFR nanobodies can be conjugated to various molecules such as drugs, peptides, toxins and photosensitizers. These nanobodies can be designed as novel immunoconjugates using the universal modular antibody-based platform technology (UniCAR). Furthermore, Anti-EGFR nanobodies can be expressed in neural stem cells and visualised by effective fluorescent and radioisotope labelling.
|
Authors | Rajan K Tripathy, Abhay H Pande |
Journal | Life sciences
(Life Sci)
Vol. 345
Pg. 122593
(May 15 2024)
ISSN: 1879-0631 [Electronic] Netherlands |
PMID | 38554946
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2024 Elsevier Inc. All rights reserved. |
Chemical References |
- Antibodies
- EGFR protein, human
- ErbB Receptors
- Single-Domain Antibodies
|
Topics |
- Humans
- Antibodies
- Cell Line, Tumor
- ErbB Receptors
(antagonists & inhibitors, immunology, metabolism)
- Precision Medicine
- Single-Domain Antibodies
(immunology, pharmacology, therapeutic use)
|